Company intelligence / Profile preview

Demegen, Inc.

Pittsburgh, Pennsylvania, United Statespitchbook.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Demegen developed novel peptide-based therapeutics targeting bacterial and fungal infections. Its lead program, Demegel, reached Phase 3 trials for bacterial infections but was not approved. PAC–113 advanced to Phase 2 trials for oral candidiasis. Some programs have been discontinued or licensed out to other companies such as Pacgen Biopharmaceuticals. There are no recent clinical results indicating ongoing activity or approvals

Therapeutic areas: OtherInfectious Diseases
Modalities: Recombinant polypeptideSmall molecule drugNatural peptides
Industry: Biotech

Drug pipeline

1 asset

P-113D

Preclinical

Partnerships

Pacgen Biopharmaceuticals (licensed compounds for oral diseases)DFB Pharmaceuticals LLC (listed as an active organization related to a program)

Beyond the preview

Go deeper on Demegen, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Demegen, Inc..

Explore the full profile